Read Our Latest Whitepaper Here

Learn how the OrganoPlate® was used to model immune cell interaction in endothelial inflammation to establish a model ideal for routine target screening towards the treatment of chronic vascular inflammation.

Cells in vivo experience a complex, three-dimensional environment that exposes them to circulating molecules, neighboring cells, and the extracellular matrix (ECM). Organ-on-a-Chip is a powerful technology driving human relevance by utilizing microfluidic techniques. Organ-on-a-Chip systems, such as the MIMETAS OrganoPlate® platform, aim to mimic cell-matrix and cell-cell interactions, and recreates human tissue microenvironment in vitro. Since most platform technologies are either based on single chips or small numbers of chips in dedicated surroundings, applications for Organ-on-a-chip are largely envisioned in pre-clinical testing. MIMETAS’ platform combines physiological relevance with scalability to enable the potential of automation, facilitating upscaling and streamlining research processes. In this white paper, we give a detailed report on a 1546 compound screen on a robust 3D angiogenic sprouting assay. Download the white paper to learn exactly how we combined the OrganoPlate® platform with an automated workflow to deploy it as a high-throughput screening tool. You will also explore how image-based phenotypic screening offers high-resolution information and generates selective hits and novel biological insights.

Cancer remains a formidable challenge worldwide, necessitating innovative solutions and the critical need for models that precisely mimic human responses, given the high failure rates in clinical trials. This whitepaper reveals how MIMETAS's pioneering organ-on-a-chip technology and 3D tissue modeling expertise represent a significant advancement in closing the translational gap in cancer drug discovery. MIMETAS' cancer modeling capabilities are showcased through six case studies, highlighting our ability to model processes such as immune cell migration, CAR T cell efficacy, and the TME's complex interactions, all contributing to drug discovery progress.

Developing effective therapies for immunological diseases remains a major challenge due to the complexity of the immune system and limitations in traditional preclinical models. Many promising drug candidates fail in clinical trials due to a lack of predictive accuracy in existing in vitro and in vivo models. This whitepaper examines how advanced 3D tissue models can improve translational relevance in immunology drug discovery, addressing key challenges in diseases such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Key Topics Covered: The biggest challenges in immunology drug discovery – and how to overcome them Breakthrough 3D tissue models for vascular inflammation, IBD, and CKD research Case studies showcasing real-world applications in immunology drug testing How advanced microphysioloigical systems improve therapeutic efficacy predictions How 3D human tissue models can enhance drug screening and mechanistic insights.

The article compares angiogenesis and vasculogenesis, highlighting the limitations of current in vitro models. It calls for more physiologically relevant models to better replicate blood vessel formation processes.